Fiche publication
Date publication
janvier 2020
Journal
Therapeutic advances in medical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe
,
Pr BOUCHE Olivier
,
Pr GHIRINGHELLI François
,
Mme JACQUIN Marion
,
Dr VERNEREY Dewi
,
Dr KAMINSKY Marie-Christine
,
Dr KIM Stephano
,
Dr LAKKIS Zaher
,
Mme MEURISSE Aurélia
Tous les auteurs :
Kim S, Meurisse A, Spehner L, Stouvenot M, François E, Buecher B, André T, Samalin E, Jary M, Nguyen T, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, de la Fouchardiere C, Boulbair F, Lakkis Z, Klajer E, Jacquin M, Taieb J, Vendrely V, Vernerey D, Borg C
Lien Pubmed
Résumé
The addition of docetaxel to cisplatin and 5-fluorouracil (DCF) has shown promising efficacy in advanced squamous cell carcinoma of the anus (SCCA). Preliminary results of Epitopes-HPV01 study showed a high rate of long-lasting complete response to DCF. The prospective, multicenter, Epitopes-HPV02 trial then confirmed the high efficacy of the modified DCF (mDCF) regimen in terms of complete response rate and long-term survival in metastatic or non-resectable locally advanced recurrent SCCA. Here, we present updated results of the Epitopes-HPV01 and Epitopes-HPV02 studies.
Mots clés
advanced, anal squamous cell carcinoma, chemotherapy, docetaxel, metastatic
Référence
Ther Adv Med Oncol. 2020 ;12:1758835920975356
